Symmetry Partners LLC Buys Shares of 14,764 DexCom, Inc. (NASDAQ:DXCM)

Symmetry Partners LLC purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 14,764 shares of the medical device company’s stock, valued at approximately $990,000.

Several other institutional investors have also modified their holdings of the stock. Norden Group LLC purchased a new position in DexCom during the first quarter worth about $2,227,000. Palisade Asset Management LLC purchased a new position in DexCom in the first quarter worth approximately $171,000. Tokio Marine Asset Management Co. Ltd. raised its position in DexCom by 5.0% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 10,188 shares of the medical device company’s stock valued at $1,413,000 after purchasing an additional 485 shares during the period. Tobam lifted its stake in shares of DexCom by 16.1% in the 1st quarter. Tobam now owns 1,988 shares of the medical device company’s stock valued at $276,000 after purchasing an additional 275 shares during the last quarter. Finally, Fidelis Capital Partners LLC acquired a new position in shares of DexCom in the 1st quarter valued at $238,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analysts Set New Price Targets

DXCM has been the topic of a number of recent analyst reports. Sanford C. Bernstein upped their target price on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. Royal Bank of Canada lowered their price objective on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Piper Sandler reissued an “overweight” rating and issued a $90.00 target price on shares of DexCom in a research report on Monday, August 26th. JPMorgan Chase & Co. upped their price target on DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Finally, StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a research note on Saturday. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $104.59.

Insiders Place Their Bets

In other news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other DexCom news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.30% of the stock is owned by company insiders.

DexCom Stock Down 0.2 %

Shares of DexCom stock traded down $0.13 during trading on Friday, hitting $70.35. 2,735,060 shares of the stock were exchanged, compared to its average volume of 3,907,564. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The firm’s 50-day moving average price is $69.85 and its 200 day moving average price is $95.92. The stock has a market cap of $27.48 billion, a price-to-earnings ratio of 42.13, a price-to-earnings-growth ratio of 2.20 and a beta of 1.18. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.